Gene Helps Predict Response to Chemotherapy in Ovarian Cancer


Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British